Fate Therapeutics (NASDAQ:FATE) Upgraded by BMO Capital Markets
Fate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, stock rose 1.26% (As on July…
